|
Novo Nordisk A/S - Press Releases
|
Novo Nordisk A/S - Press Releases
|
-
Clinical study shows liraglutide reduced blood sugar, weight and blood pressure in patients with type 2 diabetes
Phase 3 data highlight sustained efficacy and benefits of early treatment with liraglutide versus glimepiride
-
Over 70% of patients reach target with NovoMix® 30 in largest ever diabetes study
[San Francisco, USA] - New data from the IMPROVE? study show that significant improvements in glycaemic (blood sugar) control can be achieved with premixed modern insulin, NovoMix® 30, in patients poorly controlled on other, or no previous pharmaceutical treatment. The results were announced over the weekend at the 68th annual meeting of the American Diabetes Association (ADA) in San Francisco.
-
New data from head-to-head study confirms once-daily Levemir® is as effective as glargine over a 24-hour period in subjects with type 2 diabetes
San Francisco ? A head-to-head study announced over the weekend at the American Diabetes Association (ADA) meeting demonstrated that Levemir® (insulin detemir [rDNA origin] injection) can be used once daily and had a comparable blood glucose response to insulin glargine over a 24-hour period in patients with type 2 diabetes.
-
Novo Nordisk and Neose announce completion of initial phase 1 clinical trial of NN7128 (long-acting factor VIIa)
COPENHAGEN, Denmark, and HORSHAM, PA ? Novo Nordisk A/S (NYSE:NVO) and Neose Technologies, Inc. (Nasdaq GM: NTEC) today announced that Novo Nordisk has completed the initial phase 1 clinical trial with NN7128 (GlycoPEGylated factor VIIa), a long-acting version of NovoSeven® coagulation factor FVIIa (recombinant) administered intravenously. The trial assessed the safety and pharmacokinetics of NN7128 in 30 healthy subjects.
-
New studies show FlexPen® superiority to SoloStar® in dose accuracy
Two independent studies show that FlexPen® is more accurate when delivering insulin than other pens like the newly launched prefilled device, SoloStar®, from Sanofi-Aventis, which FlexPen® significantly outperformed in both studies.
-
Novo Nordisk researchers nominated for Europe?s top innovation prize
A team of researchers from Novo Nordisk is nominated for Europe?s top innovation prize, Inventor of the Year 2008 Award, that will be presented at a ceremony in Ljubljana, Slovenia, on 6 May by the European Patent Office and the European Commission.
-
Novo Nordisk donation aids Chinese pharmaceutical development and WHO efforts to combat neglected diseases
Novo Nordisk today announced a scientific collaboration that will benefit both Chinese pharmaceutical development and WHO efforts to combat neglected diseases.
-
Novo Nordisk wins design award for NovoFine® Autocover®
Novo Nordisk has been awarded a 2008 Medical Design Excellence Award for NovoFine® Autocover® ? a needle for insulin injection designed especially to reduce the risk of needle stick injuries and help people with diabetes who suffer from needle anxiety.
-
TransTech Pharma, Inc. Acquires Three Programs for the Treatment of Metabolic Disorders from Novo Nordisk
High Point, NC, US, and Bagsværd, Denmark ? TransTech Pharma, Inc. and Novo Nordisk A/S announced today that TransTech has acquired all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders. This portfolio is comprised of three distinct therapeutic approaches to such treatment: H3 receptor antagonists, PPAR? agonists and 11?HSD1 inhibitors.
-
Novo Nordisk licenses global rights to potential new haemostasis therapy
Novo Nordisk has entered a global licence agreement with French biotechnology company C2X Pharma and the French national institute for health and medical research (Inserm) for thrombin-activable factor X. The protein, which is in early preclinical development, is a novel type of bypassing agent, capable of propagating blood clotting independently of factors VIII and IX. Novo Nordisk intends to explore the protein?s potential for becoming a new treatment option for haemophilia and other critical bleeding conditions.
|
|
Explore the first worldwide Web 2.0 pharmaceutical news portal and 'Vote', 'Comment' or 'Submit' pharmaceutical news articles or other pharmaceutical web resources!
news
European Commission - Pharmaceuticals
US Food and Drug Administration 
